Rachev E, Katsarova M, Trepechov S
Akush Ginekol (Sofiia). 1989;28(3):78-81.
Clinical and laboratory study was carried out on 28 women, aged 47,80 years on the average, with uterine bleedings during the premenopausal phase of climacterium and accompanying neurovegetative climacteric symptoms. A cyclic preparation, containing 2 mg of estradiol-17 valerate in the first 11 tablets and the same dose of estrogen with supplement of 0.5 mg of norgestrel in the following 10 tablets was used for a period of 3 months(84 cycles in all). The preparation eliminated efficiently climacteric symptoms in addition to its assurance provision of stable clinical characteristic of succeeding pseudomenstrual symptoms cycles. The preparation did not induce increased thrombogenic risk, because the basic hemostatic indices before and after treatment were not changed. Lipid profile was not altered substantially as there was a favourable tendency to its occurrence in antiatherogenic direction (a reduction of LDL- and VLDL-cholesterol).
对平均年龄47至80岁、处于更年期绝经前阶段且伴有子宫出血及神经植物性更年期症状的28名女性进行了临床和实验室研究。使用一种周期制剂，前11片含2毫克戊酸雌二醇-17，后10片含相同剂量雌激素并补充0.5毫克炔诺孕酮，为期3个月（共84个周期）。该制剂有效消除了更年期症状，此外还确保了后续假月经症状周期的稳定临床特征。该制剂未引发血栓形成风险增加，因为治疗前后的基本止血指标未改变。血脂谱也未发生实质性改变，因为其出现有朝着抗动脉粥样硬化方向发展的有利趋势（低密度脂蛋白和极低密度脂蛋白胆固醇降低）。
